HOME >> BIOLOGY >> NEWS
Jefferson scientists use gene therapy to reverse heart failure in animals

(PHILADELPHIA) Heart researchers at the Center for Translational Medicine at Jefferson Medical College have used gene therapy to reverse heart failure in animals. In addition, they found that this gene therapy strategy had "unique and additive effects" to currently used, standard heart failure drugs called beta-blockers.

Reporting in the American Heart Association journal Circulation, researchers led by Walter J. Koch, Ph.D., director of the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, used a virus to carry the gene for a protein, S100A1, into the heart cells of rats with heart failure. The virus expressed the S100A1 gene only in heart cells and not in other organs, essentially making it a tailored therapy. After 18 weeks, those animals that received the gene therapy had significantly improved heart function compared to animals that did not receive the treatment.

Specifically, the Koch team, including Patrick Most, M.D., and Joseph Rabinowitz, Ph.D., also in Jefferson's Center for Translational Medicine, experimentally produced heart failure in the animals, which is characterized by a dramatic reduction in the heart's pumping ability. The scientists then delivered a modified adeno-associated virus (AAV) that contained the S100A1 gene to the heart's coronary arteries with the help of a novel heart-specific "gene promoter" that enabled the gene to be present only in heart cells.

The rats with heart failure were then followed for another two months, when their heart pumping function was monitored again. The animals that received the gene therapy had significantly better heart-pumping abilities compared to the pre-gene therapy level, and overall, the S100A1-treated rats had improved heart health. The researchers found this in both individual heart cells and in the whole
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
23-May-2007


Page: 1 2 3

Related biology news :

1. Jefferson scientists patent dramatically improves
2. Marker predicts pancreatic cancer outcome after surgery, Jefferson surgeon finds
3. Tiny genes may increase cancer susceptibility, Jefferson scientists find
4. Jefferson researchers discovery may change thinking on how viruses invade the brain
5. Jefferson scientists identify protein key to breast cancer spread, potential new drug target
6. Jefferson scientists find rabies-based vaccine could be effective against HIV
7. Jefferson scientists uncover gene mutation that cuts colon polyps, may suppress cancer
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Jefferson scientists find guardian genes choices crucial to stopping cancer process
10. Jefferson researchers uncover new way nature turns genes on and off
11. Jefferson researchers develop combined procedure for uterine preservation in treating fibroids

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:12/2/2016)... AUSTIN, Texas , Dec. 1, 2016 /PRNewswire/ ... provider, today announced BioLock , an electrocardiogram ... and health monitoring, a key IoT asset. The ... embedded into a vehicle,s steering wheel and mobile ... a simple touch. As vehicle technology ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... ... December 07, 2016 , ... A new ... the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet ... population and timing of blood sampling may improve the value of a blood-based ...
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - OncoQuest ... development and commercialization of immunotherapeutic products for the ... entered into an Antibody Manufacturing Development Program with ... , USA) for its oregovomab antibody product. Supported ... Phase IIb clinical study in ovarian cancer patients, ...
(Date:12/7/2016)... , Dec. 7, 2016  Biocom, the association for the ... statement below following passage of 21 st Century Cures ... November 30 by a 392-26 vote and in the Senate ... be attributed to Joe Panetta , president & CEO ... will give hope to millions of patients around the world. ...
(Date:12/7/2016)... , Dec. 7, 2016  Genprex, Inc. ... revolutionary immunogene therapy treatments, today announced that it ... within a leading strategic communications and advisory firm, ... program. The program will combine investor relations, public ... of raising the profile of Genprex and its ...
Breaking Biology Technology:
Cached News: